The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
Authors:
- Maria Ida MaiorinoMaria Ida Maiorino
- Michela PetrizzoMPMichela Petrizzo
- Annalisa CapuanoACAnnalisa Capuano
- Dario GiuglianoDGDario Giugliano
- Katherine EspositoKEKatherine Esposito
- 27 March 2014
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 14 (6) , 799-808
Abstract
The basal insulin products currently on market do not optimally mimic endogenous insulin secretion. These unmet clinical needs have fueled the development of new basal insulin analogues for improving their pharmacokinetics/pharmacodynamics profile.Keywords
This publication has 34 references indexed in Scilit:
- Self-Mixed/Split Insulin Regimen: A Serious Omission in the ADA/EASD Position StatementDiabetes Care, 2013
- Clinical Inertia in People With Type 2 DiabetesDiabetes Care, 2013
- Humalog (lispro) for type 2 diabetesExpert Opinion on Biological Therapy, 2012
- The Past 200 Years in DiabetesNew England Journal of Medicine, 2012
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetesExpert Opinion on Biological Therapy, 2012
- Clinical Inertia as a Clinical SafeguardJAMA, 2011
- Refining basal insulin therapy: what have we learned in the age of analogues?Diabetes/Metabolism Research and Reviews, 2007
- The Physiologic Replacement of InsulinNew England Journal of Medicine, 1989
- Rat Insulin Genes: Construction of Plasmids Containing the Coding SequencesScience, 1977